State Street Corp Purchases 148,491 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

State Street Corp raised its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 4.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,770,826 shares of the company's stock after purchasing an additional 148,491 shares during the quarter. State Street Corp owned approximately 4.42% of Syndax Pharmaceuticals worth $72,588,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SNDX. Sofinnova Investments Inc. increased its position in shares of Syndax Pharmaceuticals by 33.9% during the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company's stock valued at $44,215,000 after buying an additional 545,129 shares during the period. First Turn Management LLC boosted its position in Syndax Pharmaceuticals by 85.4% during the 3rd quarter. First Turn Management LLC now owns 1,187,165 shares of the company's stock valued at $22,853,000 after acquiring an additional 546,776 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Syndax Pharmaceuticals by 56.3% during the 2nd quarter. Millennium Management LLC now owns 1,065,508 shares of the company's stock worth $21,875,000 after acquiring an additional 383,634 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $15,165,000. Finally, Eventide Asset Management LLC bought a new position in shares of Syndax Pharmaceuticals in the 3rd quarter worth approximately $15,150,000.

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX traded up $0.04 during mid-day trading on Wednesday, reaching $13.67. The stock had a trading volume of 548,097 shares, compared to its average volume of 1,209,354. The stock has a market cap of $1.17 billion, a PE ratio of -3.75 and a beta of 0.86. Syndax Pharmaceuticals, Inc. has a 1 year low of $13.26 and a 1 year high of $25.34. The company has a fifty day moving average price of $17.63 and a 200 day moving average price of $19.38.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same period in the previous year, the company earned ($0.73) earnings per share. As a group, equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. lifted their price target on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an "overweight" rating in a research report on Thursday, November 21st. Citigroup boosted their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, November 19th. HC Wainwright reaffirmed a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th. UBS Group started coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a "buy" rating and a $37.00 price target for the company. Finally, The Goldman Sachs Group upped their price objective on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $37.64.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).